Oleuropein aglycone protects against pyroglutamylated-3 amyloid-ß toxicity: Biochemical, epigenetic and functional correlates

Neurobiology of Aging

Volumn 36, Issue 2, 2015, Pages 648-663

  Luccarini, Ilaria ^a   Grossi, Cristina ^a   Rigacci, Stefania ^a   Coppi, Elisabetta ^a   Pugliese, Anna Maria ^a   Pantano, Daniela ^a   la Marca, Giancarlo ^a,b   Ed Dami, Teresa ^a,b   Berti, Andrea ^a   Stefani, Massimo ^a   Casamenti, Fiorella ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

Author keywords

Alzheimer's disease; Epigenetics; Glutaminyl cyclase; Long term potentiation; Oleuropein aglycone; Pyroglutamylated 3 A ; TgCRND8 mice

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; HISTONE DEACETYLASE 2; HISTONE H3; HISTONE H4; NEUROPROTECTIVE AGENT; OLEUROPEIN AGLYCONE; PHENOL; PYROGLUTAMYLATED 3 AMYLOID BETA PROTEIN; UNCLASSIFIED DRUG; AMYLOID BETA-PROTEIN (1-42); HISTONE; IRIDOID; OLEUROPEIN; OLIVE OIL; PEPTIDE FRAGMENT; PROTEIN AGGREGATE; VEGETABLE OIL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; AUTOPHAGY; BIOCHEMISTRY; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; EPIGENETICS; HISTONE ACETYLATION; HISTOPATHOLOGY; IN VITRO STUDY; MOUSE; NEUROPROTECTION; NONHUMAN; PROTEIN AGGREGATION; PROTEIN EXPRESSION; ALZHEIMER DISEASE; ANIMAL; BRAIN; CHEMICAL PHENOMENA; CHEMISTRY; DIET SUPPLEMENTATION; DISEASE COURSE; DRUG EFFECTS; FEMALE; GENETIC EPIGENESIS; MALE; METABOLISM; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; AUTOPHAGY; BRAIN; DEPRESSION, CHEMICAL; DIETARY SUPPLEMENTS; DISEASE PROGRESSION; EPIGENESIS, GENETIC; FEMALE; HISTONE DEACETYLASE 2; HISTONES; IRIDOIDS; MALE; MICE, TRANSGENIC; PEPTIDE FRAGMENTS; PLANT OILS; PROTEIN AGGREGATES;

EID: 84922840562     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.08.029     Document Type: Article

References (68)

1. Adwan L., Zawia N.H. Epigenetics: a novel therapeutic approach for the treatment of Alzheimer's disease. Pharmacol. Ther. 2013, 139:41-50.
2. Alexandru A., Jagla W., Graubner S., Becker A., Bauscher C., Kohlmann S., Sedlmeier R., Raber K.A., Cynis H., Ronicke R., Reymann K.G., Petrasch-Parwez E., Hartlage-Rubsamen M., Waniek A., Rossner S., Schilling S., Osmand A.P., Demuth H.U., von Horsten S. Selective hippocampal neurodegeneration in transgenic mice expressing small amounts of truncated Abeta is induced by pyroglutamate-Abeta formation. J.Neurosci. 2011, 31:12790-12801.
3. Anderson W.W., Collingridge G.L. The LTP program: a data acquisition program for on-line analysis of long-term potentiation and other synaptic events. J.Neurosci. Methods 2001, 108:71-83.
4. Antonios G., Saiepour N., Bouter Y., Richard B.C., Paetau A., Verkkoniemi-Ahola A., Lannfelt L., Ingelsson M., Kovacs G.G., Pillot T., Wirths O., Bayer T.A. N-truncated Abeta starting with position four: early intraneuronal accumulation and rescue of toxicity using NT4X-167, a novel monoclonal antibody. Acta Neuropathol. Commun. 2013, 1:56.
5. Arrieta-Cruz I., Wang J., Pavlides C., Pasinetti G.M. Carvedilol reestablishes long-term potentiation in a mouse model of Alzheimer's disease. J.Alzheimers Dis. 2010, 21:649-654.
6. Barten D.M., Fanara P., Andorfer C., Hoque N., Wong P.Y., Husted K.H., Cadelina G.W., Decarr L.B., Yang L., Liu V., Fessler C., Protassio J., Riff T., Turner H., Janus C.G., Sankaranarayanan S., Polson C., Meredith J.E., Gray G., Hanna A., Olson R.E., Kim S.H., Vite G.D., Lee F.Y., Albright C.F. Hyperdynamic microtubules, cognitive deficits, and pathology are improved in tau transgenic mice with low doses of the microtubule-stabilizing agent BMS-241027. J.Neurosci. 2012, 32:7137-7145.
7. Bayer T.A., Wirths O. Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer's disease. Acta Neuropathol. 2014, 127:787-801.
8. Bellucci A., Rosi M.C., Grossi C., Fiorentini A., Luccarini I., Casamenti F. Abnormal processing of tau in the brain of aged TgCRND8 mice. Neurobiol. Dis. 2007, 27:328-338.
9. Bie B., Wu J., Yang H., Xu J.J., Brown D.L., Naguib M. Epigenetic suppression of neuroligin 1 underlies amyloid-induced memory deficiency. Nat. Neurosci. 2014, 17:223-231.
10. Bockers T.M., Kreutz M.R., Pohl T. Glutaminyl-cyclase expression in the bovine/porcine hypothalamus and pituitary. J.Neuroendocrinol. 1995, 7:445-453.
11. Chishti M.A., Yang D.S., Janus C., Phinney A.L., Horne P., Pearson J., Strome R., Zuker N., Loukides J., French J., Turner S., Lozza G., Grilli M., Kunicki S., Morissette C., Paquette J., Gervais F., Bergeron C., Fraser P.E., Carlson G.A., George-Hyslop P.S., Westaway D. Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695. J.Biol. Chem. 2001, 276:21562-21570.
12. Cynis H., Scheel E., Saido T.C., Schilling S., Demuth H.U. Amyloidogenic processing of amyloid precursor protein: evidence of a pivotal role of glutaminyl cyclase in generation of pyroglutamate-modified amyloid-beta. Biochemistry 2008, 47:7405-7413.
13. Cynis H., Schilling S., Bodnar M., Hoffmann T., Heiser U., Saido T.C., Demuth H.U. Inhibition of glutaminyl cyclase alters pyroglutamate formation in mammalian cells. Biochim. Biophys. Acta 2006, 1764:1618-1625.
14. De Bock M., Thorstensen E.B., Derraik J.G., Henderson H.V., Hofman P.L., Cutfield W.S. Human absorption and metabolism of oleuropein and hydroxytyrosol ingested as olive (Olea europaea L.) leaf extract. Mol. Nutr. Food Res. 2013, 57:2079-2085.
15. Del Vecchio R.A., Gold L.H., Novick S.J., Wong G., Hyde L.A. Increased seizure threshold and severity in young transgenic CRND8 mice. Neurosci. Lett. 2004, 367:164-167.
16. Fiorentini A., Rosi M.C., Grossi C., Luccarini I., Casamenti F. Lithium improves hippocampal neurogenesis, neuropathology and cognitive functions in APP mutant mice. PLoS One 2010, 5:e14382.
17. Fischer W.H., Spiess J. Identification of a mammalian glutaminyl cyclase converting glutaminyl into pyroglutamyl peptides. Proc. Natl. Acad. Sci. U. S. A 1987, 84:3628-3632.
18. Fitzjohn S.M., Morton R.A., Kuenzi F., Davies C.H., Seabrook G.R., Collingridge G.L. Similar levels of long-term potentiation in amyloid precursor protein -null and wild-type mice in the CA1 region of picrotoxin treated slices. Neurosci. Lett. 2000, 288:9-12.
19. Frost J.L., Le K.X., Cynis H., Ekpo E., Kleinschmidt M., Palmour R.M., Ervin F.R., Snigdha S., Cotman C.W., Saido T.C., Vassar R.J., George-Hyslop P., Ikezu T., Schilling S., Demuth H.U., Lemere C.A. Pyroglutamate-3 amyloid-beta deposition in the brains of humans, non-human primates, canines, and Alzheimer disease-like transgenic mouse models. Am. J. Pathol. 2013, 183:369-381.
20. Galvano F., La Fauci L., Graziani G., Ferracane R., Masella R., Di Giacomo C., Scacco A., D'Archivio M., Vanella L., Galvano G. Phenolic compounds and antioxidant activity of Italian extra virgin olive oil Monti Iblei. J.Med. Food 2007, 10:650-656.
21. Gendron T.F., Petrucelli L. The role of tau in neurodegeneration. Mol. Neurodegener. 2009, 4:13.
22. Giacobini E., Gold G. Alzheimer disease therapy-moving from amyloid-beta to tau. Nat. Rev. Neurol. 2013, 9:677-686.
23. Govindarajan N., Agis-Balboa R.C., Walter J., Sananbenesi F., Fischer A. Sodium butyrate improves memory function in an Alzheimer's disease mouse model when administered at an advanced stage of disease progression. J.Alzheimers Dis. 2011, 26:187-197.
24. Govindarajan N., Rao P., Burkhardt S., Sananbenesi F., Schluter O.M., Bradke F., Lu J., Fischer A. Reducing HDAC6 ameliorates cognitive deficits in a mouse model for Alzheimer's disease. EMBO Mol. Med. 2013, 5:52-63.
25. Graff J., Kim D., Dobbin M.M., Tsai L.H. Epigenetic regulation of gene expression in physiological and pathological brain processes. Physiol. Rev. 2011, 91:603-649.
26. Graff J., Rei D., Guan J.S., Wang W.Y., Seo J., Hennig K.M., Nieland T.J., Fass D.M., Kao P.F., Kahn M., Su S.C., Samiei A., Joseph N., Haggarty S.J., Delalle I., Tsai L.H. An epigenetic blockade of cognitive functions in the neurodegenerating brain. Nature 2012, 483:222-226.
27. Gray S.G. Epigenetic treatment of neurological disease. Epigenomics 2011, 3:431-450.
28. Grossi C., Rigacci S., Ambrosini S., Ed Dami T., Luccarini I., Traini C., Failli P., Berti A., Casamenti F., Stefani M. The polyphenol oleuropein aglycone protects TgCRND8 mice against Aß plaque pathology. PLoS One 2013, 8:e71702. In Press.
29. Gunn A.P., Masters C.L., Cherny R.A. Pyroglutamate-Abeta: role in the natural history of Alzheimer's disease. Int. J. Biochem. Cell Biol. 2010, 42:1915-1918.
30. Haass C. Take five-BACE and the gamma-secretase quartet conduct Alzheimer's amyloid beta-peptide generation. EMBO J. 2004, 23:483-488.
31. Hartlage-Rubsamen M., Morawski M., Waniek A., Jager C., Zeitschel U., Koch B., Cynis H., Schilling S., Schliebs R., Demuth H.U., Rossner S. Glutaminyl cyclase contributes to the formation of focal and diffuse pyroglutamate (pGlu)-Abeta deposits in hippocampus via distinct cellular mechanisms. Acta Neuropathol. 2011, 121:705-719.
32. Hayden E.Y., Teplow D.B. Amyloid beta-protein oligomers and Alzheimer's disease. Alzheimers Res. Ther. 2013, 5:60.
33. He W., Barrow C.J. The A beta 3-pyroglutamyl and 11-pyroglutamyl peptides found in senile plaque have greater beta-sheet forming and aggregation propensities invitro than full-length A beta. Biochemistry 1999, 38:10871-10877.
34. Henning S.M., Wang P., Carpenter C.L., Heber D. Epigenetic effects of green tea polyphenols in cancer. Epigenomics 2013, 5:729-741.
35. Jawhar S., Wirths O., Bayer T.A. Pyroglutamate amyloid-beta (Abeta): a hatchet man in Alzheimer disease. J.Biol. Chem. 2011, 286:38825-38832.
36. Jawhar S., Wirths O., Schilling S., Graubner S., Demuth H.U., Bayer T.A. Overexpression of glutaminyl cyclase, the enzyme responsible for pyroglutamate A{beta} formation, induces behavioral deficits, and glutaminyl cyclase knock-out rescues the behavioral phenotype in 5XFAD mice. J.Biol. Chem. 2011, 286:4454-4460.
37. Kilgore M., Miller C.A., Fass D.M., Hennig K.M., Haggarty S.J., Sweatt J.D., Rumbaugh G. Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology 2010, 35:870-880.
38. Kimura R., MacTavish D., Yang J., Westaway D., Jhamandas J.H. Beta amyloid-induced depression of hippocampal long-term potentiation is mediated through the amylin receptor. J.Neurosci. 2012, 32:17401-17406.
39. Konno K., Hirayama C., Yasui H., Nakamura M. Enzymatic activation of oleuropein: a protein crosslinker used as a chemical defense in the privet tree. Proc. Natl. Acad. Sci. U. S. A 1999, 96:9159-9164.
40. Lee S.J., Krauthauser C., Maduskuie V., Fawcett P.T., Olson J.M., Rajasekaran S.A. Curcumin-induced HDAC inhibition and attenuation of medulloblastoma growth invitro and invivo. BMC Cancer 2011, 11:144.
41. Lemere C.A., Lopera F., Kosik K.S., Lendon C.L., Ossa J., Saido T.C., Yamaguchi H., Ruiz A., MartInez A., Madrigal L., Hincapie L., Arango J.C., Anthony D.C., Koo E.H., Goate A.M., Selkoe D.J., Arango J.C. The E280A presenilin 1 Alzheimer mutation produces increased A beta 42 deposition and severe cerebellar pathology. Nat. Med. 1996, 2:1146-1150.
42. Li W., Zhu S., Li J., Assa A., Jundoria A., Xu J., Fan S., Eissa N.T., Tracey K.J., Sama A.E., Wang H. EGCG stimulates autophagy and reduces cytoplasmic HMGB1 levels in endotoxin-stimulated macrophages. Biochem. Pharmacol. 2011, 81:1152-1163.
43. Lithner C.U., Lacor P.N., Zhao W.Q., Mustafiz T., Klein W.L., Sweatt J.D., Hernandez C.M. Disruption of neocortical histone H3 homeostasis by soluble Abeta: implications for Alzheimer's disease. Neurobiol. Aging 2013, 34:2081-2090.
44. Morawski M., Schilling S., Kreuzberger M., Waniek A., Jager C., Koch B., Cynis H., Kehlen A., Arendt T., Hartlage-Rubsamen M., Demuth H.U., Rossner S. Glutaminyl cyclase in human cortex: correlation with (pGlu)-amyloid-beta load and cognitive decline in Alzheimer's disease. J.Alzheimers Dis. 2014, 39:385-400.
45. Mori H., Takio K., Ogawara M., Selkoe D.J. Mass spectrometry of purified amyloid beta protein in Alzheimer's disease. J.Biol. Chem. 1992, 267:17082-17086.
46. Nussbaum J.M., Schilling S., Cynis H., Silva A., Swanson E., Wangsanut T., Tayler K., Wiltgen B., Hatami A., Ronicke R., Reymann K., Hutter-Paier B., Alexandru A., Jagla W., Graubner S., Glabe C.G., Demuth H.U., Bloom G.S. Prion-like behaviour and tau-dependent cytotoxicity of pyroglutamylated amyloid-beta. Nature 2012, 485:651-655.
47. Palop J.J., Chin J., Roberson E.D., Wang J., Thwin M.T., Bien-Ly N., Yoo J., Ho K.O., Yu G.Q., Kreitzer A., Finkbeiner S., Noebels J.L., Mucke L. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 2007, 55:697-711.
48. Pan M.H., Lai C.S., Wu J.C., Ho C.T. Epigenetic and disease targets by polyphenols. Curr. Pharm. Des. 2013, 19:6156-6185.
49. Paxinos G., Franklin K.B.J. The Mouse Brain in Stereotaxic Coordinates 2001, Academic Press.
50. Pugliese A.M., Traini C., Cipriani S., Gianfriddo M., Mello T., Giovannini M.G., Galli A., Pedata F. The adenosine A2A receptor antagonist ZM241385 enhances neuronal survival after oxygen-glucose deprivation in rat CA1 hippocampal slices. Br. J. Pharmacol. 2009, 157:818-830.
51. Rigacci S., Guidotti V., Bucciantini M., Nichino D., Relini A., Berti A., Stefani M. Abeta(1-42) aggregates into non-toxic amyloid assemblies in the presence of the natural polyphenol oleuropein aglycon. Curr. Alzheimer Res. 2011, 8:841-852.
52. Rigacci S., Guidotti V., Bucciantini M., Parri M., Nediani C., Cerbai E., Stefani M., Berti A. Oleuropein aglycon prevents cytotoxic amyloid aggregation of human amylin. J.Nutr. Biochem. 2010, 21:726-735.
53. Rosi M.C., Luccarini I., Grossi C., Fiorentini A., Spillantini M.G., Prisco A., Scali C., Gianfriddo M., Caricasole A., Terstappen G.C., Casamenti F. Increased Dickkopf-1 expression in transgenic mouse models of neurodegenerative disease. J.Neurochem. 2010, 112:1539-1551.
54. Saido T.C., Iwatsubo T., Mann D.M., Shimada H., Ihara Y., Kawashima S. Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. Neuron 1995, 14:457-466.
55. Schilling S., Hoffmann T., Manhart S., Hoffmann M., Demuth H.U. Glutaminyl cyclases unfold glutamyl cyclase activity under mild acid conditions. FEBS Lett. 2004, 563:191-196.
56. Schilling S., Zeitschel U., Hoffmann T., Heiser U., Francke M., Kehlen A., Holzer M., Hutter-Paier B., Prokesch M., Windisch M., Jagla W., Schlenzig D., Lindner C., Rudolph T., Reuter G., Cynis H., Montag D., Demuth H.U., Rossner S. Glutaminyl cyclase inhibition attenuates pyroglutamate Abeta and Alzheimer's disease-like pathology. Nat. Med. 2008, 14:1106-1111.
57. Selkoe D.J., Schenk D. Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu. Rev. Pharmacol. Toxicol. 2003, 43:545-584.
58. Serra A., Rubio L., Borras X., Macia A., Romero M.P., Motilva M.J. Distribution of olive oil phenolic compounds in rat tissues after administration of a phenolic extract from olive cake. Mol. Nutr. Food Res. 2012, 56:486-496.
59. Smith J.P., Lal V., Bowser D., Cappai R., Masters C.L., Ciccotosto G.D. Stimulus pattern dependence of the Alzheimer's disease amyloid-beta 42 peptide's inhibition of long term potentiation in mouse hippocampal slices. Brain Res. 2009, 1269:176-184.
60. Sung Y.M., Lee T., Yoon H., DiBattista A.M., Song J.M., Sohn Y., Moffat E.I., Turner R.S., Jung M., Kim J., Hoe H.S. Mercaptoacetamide-based class II HDAC inhibitor lowers Abeta levels and improves learning and memory in a mouse model of Alzheimer's disease. Exp. Neurol. 2013, 239:192-201.
61. Thakur V.S., Gupta K., Gupta S. Green tea polyphenols increase p53 transcriptional activity and acetylation by suppressing class I histone deacetylases. Int. J. Oncol. 2012, 41:353-361.
62. Vingtdeux V., Giliberto L., Zhao H., Chandakkar P., Wu Q., Simon J.E., Janle E.M., Lobo J., Ferruzzi M.G., Davies P., Marambaud P. AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. J.Biol. Chem. 2010, 285:9100-9113.
63. Wang J.Z., Liu F. Microtubule-associated protein tau in development, degeneration and protection of neurons. Prog. Neurobiol. 2008, 85:148-175.
64. Wang J., Yu J.T., Tan M.S., Jiang T., Tan L. Epigenetic mechanisms in Alzheimer's disease: implications for pathogenesis and therapy. Ageing Res. Rev. 2013, 12:1024-1041.
65. Wang M., Yu T., Zhu C., Sun H., Qiu Y., Zhu X., Li J. Resveratrol triggers protective autophagy through the ceramide/Akt/mTOR pathway in melanoma B16 cells. Nutr. Cancer 2014, 66:435-440.
66. Wirths O., Bethge T., Marcello A., Harmeier A., Jawhar S., Lucassen P.J., Multhaup G., Brody D.L., Esparza T., Ingelsson M., Kalimo H., Lannfelt L., Bayer T.A. Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer's disease cases. J.Neural Transm. 2010, 117:85-96.
67. Wirths O., Breyhan H., Cynis H., Schilling S., Demuth H.U., Bayer T.A. Intraneuronal pyroglutamate-Abeta 3-42 triggers neurodegeneration and lethal neurological deficits in a transgenic mouse model. Acta Neuropathol. 2009, 118:487-496.
68. Zhang B.K., Lai Y.Q., Niu P.P., Zhao M., Jia S.J. Epigallocatechin-3-gallate inhibits homocysteine-induced apoptosis of endothelial cells by demethylation of the DDAH2 gene. Planta Med. 2013, 79:1715-1719.